A Novel 29-Messenger RNA Host-Response Assay From Whole Blood Accurately Identifies Bacterial and Viral Infections in Patients Presenting to the Emergency Department With Suspected Infections: A Prospective Observational Study
Wolfgang Bauer, Kai Kappert, Noa Galtung, Dana Lehmann, James Wacker, Henry K Cheng, Oliver Liesenfeld, Ljubomir Buturovic, Roland Luethy, Timothy E Sweeney, Rudolf Tauber, Rajan Somasundaram, Wolfgang Bauer, Kai Kappert, Noa Galtung, Dana Lehmann, James Wacker, Henry K Cheng, Oliver Liesenfeld, Ljubomir Buturovic, Roland Luethy, Timothy E Sweeney, Rudolf Tauber, Rajan Somasundaram
Abstract
Objectives: The rapid diagnosis of acute infections and sepsis remains a serious challenge. As a result of limitations in current diagnostics, guidelines recommend early antimicrobials for suspected sepsis patients to improve outcomes at a cost to antimicrobial stewardship. We aimed to develop and prospectively validate a new, 29-messenger RNA blood-based host-response classifier Inflammatix Bacterial Viral Non-Infected version 2 (IMX-BVN-2) to determine the likelihood of bacterial and viral infections.
Design: Prospective observational study.
Setting: Emergency Department, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Germany.
Patients: Three hundred twelve adult patients presenting to the emergency department with suspected acute infections or sepsis with at least one vital sign change.
Interventions: None (observational study only).
Measurements and main results: Gene expression levels from extracted whole blood RNA was quantified on a NanoString nCounter SPRINT (NanoString Technologies, Seattle, WA). Two predicted probability scores for the presence of bacterial and viral infection were calculated using the IMX-BVN-2 neural network classifier, which was trained on an independent development set. The IMX-BVN-2 bacterial score showed an area under the receiver operating curve for adjudicated bacterial versus ruled out bacterial infection of 0.90 (95% CI, 0.85-0.95) compared with 0.89 (95% CI, 0.84-0.94) for procalcitonin with procalcitonin being used in the adjudication. The IMX-BVN-2 viral score area under the receiver operating curve for adjudicated versus ruled out viral infection was 0.83 (95% CI, 0.77-0.89).
Conclusions: IMX-BVN-2 demonstrated accuracy for detecting both viral infections and bacterial infections. This shows the potential of host-response tests as a novel and practical approach for determining the causes of infections, which could improve patient outcomes while upholding antimicrobial stewardship.
Conflict of interest statement
Drs. Bauer’s, Kappert’s, Galtung’s, Lehmann’s, Tauber’s, and Somasundaram’s institution received funding from Inflammatix and Gentian AS. Dr. Kappert’s and Tauber’s institution received funding from Deutsche Forschungsgemeinschaft, Stiftung für Pathobiochemie und Molekulare Diagnostik, and Deutsche Stiftung Innere Medizin. Drs. Wacker, Liesenfeld, Buturovic, Cheng, Sweeney, and Luethy disclosed that they are employees of and option shareholders in Inflammatix.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc.
Figures
References
- Álvaro-Meca A, Jiménez-Sousa MA, Micheloud D, et al. ; Group of Biomedical Research in Critical Care Medicine (BioCritic): Epidemiological trends of sepsis in the twenty-first century (2000-2013): An analysis of incidence, mortality, and associated costs in Spain. Popul Health Metr. 2018; 16:4.
- Rhodes A, Evans LE, Alhazzani W, et al. : Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017; 45:486–552
- Seymour CW, Gesten F, Prescott HC, et al. : Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med. 2017; 376:2235–2244
- Sweeney TE, Shidham A, Wong HR, et al. : A comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene set. Sci Transl Med. 2015; 7:287ra71
- Sweeney TE, Liesenfeld O, May L: Diagnosis of bacterial sepsis: Why are tests for bacteremia not sufficient? Expert Rev Mol Diagn. 2019; 19:959–962
- Sweeney TE, Wong HR, Khatri P: Robust classification of bacterial and viral infections via integrated host gene expression diagnostics. Sci Transl Med. 2016; 8:346ra91
- Sweeney TE, Perumal TM, Henao R, et al. : Mortality prediction in sepsis via gene expression analysis: A community approach. bioRxiv. 095489
- Sweeney TE, Khatri P: Benchmarking sepsis gene expression diagnostics using public data. Crit Care Med. 2017; 45:1–10
- Mayhew MB, Buturovic L, Luethy R, et al. : A generalizable 29-mRNA neural-network classifier for acute bacterial and viral infections. Nat Commun. 2020; 11:1177.
- Huang DT, Yealy DM, Filbin MR, et al. ; ProACT Investigators: Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018; 379:236–249
- Hamade B, Huang DT: Procalcitonin: Where are we now? Crit Care Clin. 2020; 36:23–40
- Goodlet KJ, Cameron EA, Nailor MD: Low sensitivity of procalcitonin for bacteremia at an academic medical center: A cautionary tale for antimicrobial stewardship. Open Forum Infect Dis. 2020; 7:ofaa096.
- Schuetz P, Christ-Crain M, Thomann R, et al. ; ProHOSP Study Group: Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. JAMA. 2009; 302:1059–1066
- Shapiro NI, Self WH, Rosen J, et al. : A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. 2018; 50:420–429
- van Houten CB, de Groot JAH, Klein A, et al. : A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): A double-blind, multicentre, validation study. Lancet Infect Dis. 2017; 17:431–440
- Self WH, Rosen J, Sharp SC, et al. : Diagnostic accuracy of FebriDx: A rapid test to detect immune responses to viral and bacterial upper respiratory infections. J Clin Med. 2017; 6:E94.
- Srugo I, Klein A, Stein M, et al. : Validation of a novel assay to distinguish bacterial and viral infections. Pediatrics. 2017; 140:e20163453.
- Singer M, Inada-Kim M, Shankar-Hari M: Sepsis hysteria: Excess hype and unrealistic expectations. Lancet. 2019; 394:1513–1514
- Mi MY, Klompas M, Evans L: Early Administration of antibiotics for suspected sepsis. N Engl J Med. 2019; 380:593–596
Source: PubMed